Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Corporate Update (July 2026)
14 slides from Satellos Bioscience's corporate update, Jul 8, 2026
Slide 1: Six-Month TRAILHEAD Data Update
INVESTOR C ALL Six-Month TRAILHEAD Data Update Reduced muscle fat fraction, increased total effort, stable strength and favorable safety profile following treatment with SAT-3247 July 8, 2026 · NASDAQ: MSLE · TSX: MSCL REGENERATING MUSCLE FROM WITHIN
Slide 2: Legal Disclaimers
© 2026 Satellos Bioscience Legal Disclaimers This presentation includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the anticipated bene
Slide 3: TRAILHEAD: Open-Label Study in Adults with Duchenne
© 2026 Satellos Bioscience CLINICAL PROGRAM TRAILHEAD: Open-Label Study in Adults with Duchenne DESIGN TH I S R EAD O U T Population Adult males ≥16 years of age with confirmed DMD diagnosis and confirmed mutation in DMD gene; up to 30 4 expected to be enrolled (Australia & U.S.) adults who complete
Slide 4: A Consistent Picture of Stable or Improving Outcomes
© 2026 Satellos Bioscience 6-MONTH READOUT A Consistent Picture of Stable or Improving Outcomes Six-month findings in four adults (aged 21–28) with Duchenne who originally enrolled in CL-101 — one of the most challenging populations in which to show treatment effects. Favorable −3.7% +~34% ~2× Safet
Slide 5: SAT-3247 Well Tolerated; Favorable Safety Profile Maintained Through Six Months
© 2026 Satellos Bioscience SAFETY & TOLERABILITY SAT-3247 Well Tolerated; Favorable Safety Profile Maintained Through Six Months 0 0 100% 186 serious TEAEs TEAEs leading to treatment compliance days mean drug withdrawal or exposure discontinuation K E Y T AK E A W A Y No serious or treatment-limitin
Slide 6: MRI Muscle Fat-Fraction Improved in All Participants
© 2026 Satellos Bioscience MUSCLE COMPOSITION MRI Muscle Fat-Fraction Improved in All Participants Individual Values and Changes Mean Changes Natural History of Elbow Flexor Fat-Fraction1 Dixon (%) CL-101 and TRAILHEAD ages Muscle MRI Fat Fraction (%) 0 Baseline Month 5 Change -1 Mean Change (% ± SD
Slide 7: Total Effort (TE99C) Improved Over Six Months
© 2026 Satellos Bioscience REAL-WORLD FUNCTION Total Effort (TE99C) Improved Over Six Months Total Effort (99th Percentile) 14 Change from CL-101 Baseline +~34% From mean 16.1 joules/kg at baseline to 21.6 at 12 month 6; increases observed in all four participants Change from Baseline (J/kg ± SD) 10
Slide 8: Upper-Extremity Strength Maintained
© 2026 Satellos Bioscience MUSCLE STRENGTH Upper-Extremity Strength Maintained The near-doubling of handgrip strength seen in the 28-day CL-101 study was maintained through six months of TRAILHEAD follow-up. Handgrip Strength CL-101 T R AI L H E AD S T AB L E AC R O S S AL L M U S C L E G R O U P S
Slide 9: Mean Serum Creatine Kinase (CK) Concentrations Demonstrated 38% Decline
© 2026 Satellos Bioscience BIOMARKERS Mean Serum Creatine Kinase (CK) Concentrations Demonstrated 38% Decline Serum CK Time off SAT-3247: 7-11 months CK levels in TRAILHEAD are lower than those observed in CL-101 After 28 days in CL-101, an interval of 7-11 months, and 140 days in TRAILHEAD Mean CK
Slide 10: Performance of Upper Limb (PUL 2.0) Function Maintained
© 2026 Satellos Bioscience FUNCTIONAL ASSESSMENTS Performance of Upper Limb (PUL 2.0) Function Maintained PUL 2.0 2 participants 2 participants improved by 1 point remained stable 21.8 22.3 TRAILHEAD TRAILHEAD Baseline Day 140 SAT-3247 is an investigational agent not yet approved in any country or r
Slide 11: Patient Reported Quality-of-life Measure (PedsQL) Scores Demonstrated Improvement
© 2026 Satellos Bioscience PATIENT-REPORTED OUTCOMES Patient Reported Quality-of-life Measure (PedsQL) Scores Demonstrated Improvement 100 90 PedsQL Mean Total Score (score ± SD) 80 +6.94 78.47 70 71.53 60 50 Mean PedsQL-MFS scores increased (CL-101 baseline → month 6 in TRAILHEAD) 40 30 20 PedsQL d
Slide 12: Adults living with DMD continue to experience progressive muscle loss
“ © 2026 Satellos Bioscience Adults living with DMD continue to experience progressive muscle loss, making improvement in fat fraction and total effort promising, and stability across multiple clinically relevant measures as observed with SAT-3247 treatment makes these findings potentially clinicall
Slide 13: Encouraging for BASECAMP — Upcoming Catalysts
© 2026 Satellos Bioscience PATH FORWARD Encouraging for BASECAMP — Upcoming Catalysts “We believe these findings continue to show the biological activity of SAT-3247…potentially encouraging for BASECAMP, where a pediatric DMD population with greater remaining muscle mass may offer additional opportu
Slide 14: Reimagine Regenerate Realize
© 2026 Satellos Bioscience THE ROAD AHEAD Reimagine how Duchenne muscular dystrophy is treated Regenerate muscle with an oral, once-daily medicine Realize a new future for patients and families REGENERATING MUSCLE FROM WITHIN